Akero (AKRO) CEO gifts 14,739 shares; ownership now 511,375
Akero Therapeutics (AKRO) reported an insider transaction by its President and CEO, who is also a Director.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Akero Therapeutics (AKRO) reported an insider transaction by its President and CEO, who is also a Director. On 11/12/2025, the insider made a bona fide charitable gift of 14,739 shares of common stock, reported as code G at a stated price of $0. Following the transaction, the insider’s beneficial ownership stands at 511,375 shares, held directly.
The explanation notes the recipient is a 501(c)(3) organization and the reporting person has no pecuniary interest in that entity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Gift | Common Stock | 14,739 | $0.00 | $0.00 |
Footnotes (1)
- F1. The reported transaction represents a bona fide charitable gift to a 501(c)(3) organization. The Reporting Person does not have any pecuniary interest in the 501(c)(3) organization.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Akero Therapeutics (AKRO) disclose in this Form 4?
Who is the reporting person in the AKRO filing?
What does transaction code G mean in this context?
Does the reporting person have economic interest in the recipient?
AI-generated analysis. How Rhea-AI works. Not financial advice.